NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome
Luiza Handschuh(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Piotr Kozłowski(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Jacek Błażewicz(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Krzysztof Lewandowski(Poznan University of Medical Sciences), Małgorzata Marcinkowska(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Mieczysław Komarnicki(Poznan University of Medical Sciences), Magdalena Łuczak(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Paweł Wojciechowski(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Maciej Kaźmierczak(Silesian University of Technology), Marek Figlerowicz(Poznań University of Technology)
Cited by 26
Related Papers
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
|Journal of Clinical Oncology|2022|93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR
|International Journal of Oncology|2017|80
RNA degradome--its biogenesis and functions
|Nucleic Acids Research|2011|55